FDA to review Otsuka’s sibeprenlimab application for IgAN
The US FDA has accepted for review Otsuka Pharmaceutical’s biologics licence application (BLA) for the monoclonal antibody, sibeprenlimab.
The US FDA has accepted for review Otsuka Pharmaceutical’s biologics licence application (BLA) for the monoclonal antibody, sibeprenlimab.
What's Your Reaction?
